ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
NIBAN2/FLII/RREB1 Axis Drives Glioma Stem Cell Malignancy via TLR3 Pathway Activation.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Glioma stem-like cells (GSCs), characterized by self-renewal capacity, therapeutic resistance, and high tumorigenicity, are considered the fundamental drivers of glioma aggressiveness and recurrence. However, the core regulatory mechanisms underlying GSCs stemness maintenance remain unclear. In this study, we identified that the NIBAN2 is highly expressed in glioma tissues and GSCs, and its expression is closely associated with poor patient prognosis. Functional experiments demonstrated that NIBAN2 directly binds to Flightless I (FLII) and enhances its interaction with the transcription factor Ras-responsive element-binding protein 1 (RREB1), thereby promoting nuclear translocation. Together, the NIBAN2-FLII-RREB1 complex activates the Toll-like receptor (TLR3) signaling pathway, sustaining the stem-like phenotype and tumorigenic potential of GSCs. Further investigation revealed that RREB1 transcriptionally upregulates NIBAN2 and CD44, promoting the expression of the key glycolytic enzyme LDHA (Lactate Dehydrogenase A). This establishes a feed-forward signaling-transcription-metabolism axis driven by NIBAN2/FLII/RREB1, facilitating metabolic reprogramming. Multi-omics and metabolomic analyses confirmed that this loop enhances glycolytic flux to maintain GSCs' metabolic homeostasis. Drug screening identified the HIV protease inhibitor nelfinavir as a specific disruptor of the NIBAN2-FLII complex. When combined with the LDHA inhibitor FX11, it induced synergistic anti-tumor effects in organoid and patient-derived xenograft models, thereby significantly inhibiting tumor progression and prolonging survival. Clinical samples further confirmed the co-upregulation of NIBAN2, FLII, and RREB1 in GBM (Glioblastoma) tissues, which correlates with SOX2 and Ki-67 expression and poor prognosis. Collectively, this study, for the first time, reveals that NIBAN2 maintains GSCs stemness by activating FLII-RREB1 axis and TLR3 signaling, thereby establishing a feed-forward signaling-transcription-metabolism axis. This finding provides a novel strategy and potential targets for precise therapeutic intervention against glioma stemness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.